CN102665418B - 组合 - Google Patents

组合 Download PDF

Info

Publication number
CN102665418B
CN102665418B CN201080055873.2A CN201080055873A CN102665418B CN 102665418 B CN102665418 B CN 102665418B CN 201080055873 A CN201080055873 A CN 201080055873A CN 102665418 B CN102665418 B CN 102665418B
Authority
CN
China
Prior art keywords
compound
suitably
days
administered
consecutive days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080055873.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN102665418A (zh
Inventor
M.邓布尔
T.吉尔默
R.库马
S.拉奎尔
P.F.勒博维茨
S.R.莫里斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NOVA LABORATORIES Sdn Bhd
Novartis AG
Original Assignee
GlaxoSmithKline LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline LLC filed Critical GlaxoSmithKline LLC
Publication of CN102665418A publication Critical patent/CN102665418A/zh
Application granted granted Critical
Publication of CN102665418B publication Critical patent/CN102665418B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201080055873.2A 2009-10-08 2010-10-08 组合 Expired - Fee Related CN102665418B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24980309P 2009-10-08 2009-10-08
US61/249,803 2009-10-08
PCT/US2010/051907 WO2011044414A1 (en) 2009-10-08 2010-10-08 Combination

Publications (2)

Publication Number Publication Date
CN102665418A CN102665418A (zh) 2012-09-12
CN102665418B true CN102665418B (zh) 2014-10-29

Family

ID=43857162

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080055873.2A Expired - Fee Related CN102665418B (zh) 2009-10-08 2010-10-08 组合

Country Status (16)

Country Link
US (2) US8835450B2 (enExample)
EP (1) EP2485593B1 (enExample)
JP (1) JP2013507382A (enExample)
KR (1) KR20120100978A (enExample)
CN (1) CN102665418B (enExample)
AU (1) AU2010303363B2 (enExample)
BR (1) BR112012008271A2 (enExample)
CA (1) CA2777085A1 (enExample)
EA (1) EA022982B1 (enExample)
ES (1) ES2532026T3 (enExample)
IL (1) IL218999A (enExample)
MX (1) MX2012004139A (enExample)
PL (1) PL2485593T3 (enExample)
PT (1) PT2485593E (enExample)
WO (1) WO2011044414A1 (enExample)
ZA (1) ZA201202494B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ628394A (en) * 2012-04-24 2016-02-26 Glaxosmithkline Ip No 2 Ltd Treatment method for steroid responsive dermatoses
IN2015DN03909A (enExample) * 2012-10-22 2015-10-02 Glaxosmithkline Llc
MX2015005114A (es) * 2012-10-22 2015-07-17 Glaxosmithkline Llc Combinacion.
CN104109159A (zh) 2013-04-17 2014-10-22 杭州普晒医药科技有限公司 苯磺酰胺噻唑化合物的新晶型及其制备方法
WO2015003571A1 (zh) * 2013-07-08 2015-01-15 杭州普晒医药科技有限公司 达拉菲尼甲磺酸盐的新晶型及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000042003A1 (en) * 1999-01-13 2000-07-20 Warner-Lambert Company Benzenesulfonamide derivatives and their use as mek inhibitors
WO2005121142A1 (en) * 2004-06-11 2005-12-22 Japan Tobacco Inc. 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h-pyrido’2,3-d! pyrimidine derivatives and related compounds for the treatment of cancer
CN101421265A (zh) * 2006-01-18 2009-04-29 安姆根有限公司 作为蛋白激酶b(pkb)抑制剂的噻唑化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2228629T3 (es) * 1999-11-22 2005-04-16 Smithkline Beecham Plc Derivados de imidazol y su uso como inhibidores de raf-quinasa.
EP1601657A1 (en) * 2003-03-12 2005-12-07 Vertex Pharmaceuticals Incorporated Pyrazole modulators of atp-binding cassette transporters
DE102004018198A1 (de) * 2004-04-15 2005-11-03 Merck Patent Gmbh Sulfonamide
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
UA103319C2 (en) * 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000042003A1 (en) * 1999-01-13 2000-07-20 Warner-Lambert Company Benzenesulfonamide derivatives and their use as mek inhibitors
WO2005121142A1 (en) * 2004-06-11 2005-12-22 Japan Tobacco Inc. 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h-pyrido’2,3-d! pyrimidine derivatives and related compounds for the treatment of cancer
CN101421265A (zh) * 2006-01-18 2009-04-29 安姆根有限公司 作为蛋白激酶b(pkb)抑制剂的噻唑化合物

Also Published As

Publication number Publication date
EP2485593A1 (en) 2012-08-15
IL218999A0 (en) 2012-06-28
WO2011044414A1 (en) 2011-04-14
CA2777085A1 (en) 2011-04-14
CN102665418A (zh) 2012-09-12
PT2485593E (pt) 2015-04-28
EP2485593A4 (en) 2013-02-13
KR20120100978A (ko) 2012-09-12
ES2532026T3 (es) 2015-03-23
EA201270526A1 (ru) 2012-12-28
US8835450B2 (en) 2014-09-16
ZA201202494B (en) 2012-12-27
EP2485593B1 (en) 2015-01-07
IL218999A (en) 2015-08-31
BR112012008271A2 (pt) 2015-09-22
JP2013507382A (ja) 2013-03-04
PL2485593T3 (pl) 2015-06-30
MX2012004139A (es) 2012-09-07
EA022982B1 (ru) 2016-04-29
US20140350039A1 (en) 2014-11-27
US20120196886A1 (en) 2012-08-02
AU2010303363B2 (en) 2013-09-05
US9402846B2 (en) 2016-08-02
AU2010303363A1 (en) 2012-04-26

Similar Documents

Publication Publication Date Title
CN102665418B (zh) 组合
CN102647908B (zh) 组合
EP2572199B1 (en) Combination
US20150094283A1 (en) Combination
US20150272950A1 (en) Combination
AU2013334943A1 (en) Combination

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20151103

Address after: Basel, Switzerland

Patentee after: NOVARTIS AG

Address before: Basel, Switzerland

Patentee before: NOVA LABORATORIES SDN BHD

Effective date of registration: 20151103

Address after: Basel, Switzerland

Patentee after: NOVA LABORATORIES SDN BHD

Address before: American Pennsylvania

Patentee before: GLAXOSMITHKLINE LLC

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20141029

Termination date: 20171008

CF01 Termination of patent right due to non-payment of annual fee